Genor Biopharma Holdings Limited

DB:67N0 Stock Report

Market Cap: €104.4m

Genor Biopharma Holdings Past Earnings Performance

Past criteria checks 0/6

Genor Biopharma Holdings has been growing earnings at an average annual rate of 26.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 32.1% per year.

Key information

26.7%

Earnings growth rate

41.2%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate32.1%
Return on equity-49.5%
Net Margin-3,631.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Genor Biopharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:67N0 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2414-52691370
31 Mar 247-600108428
31 Dec 230-674125485
30 Sep 236-637134495
30 Jun 2313-599143504
31 Mar 2314-665180544
31 Dec 2216-730217584
30 Sep 229-800263610
30 Jun 223-870309636
31 Mar 221-868307625
31 Dec 210-865306613
30 Sep 213-1,880299617
30 Jun 217-2,895292620
31 Mar 2110-3,086281721
31 Dec 2010-3,027241697
31 Mar 2012-590116480
31 Dec 1913-52289439
31 Dec 187-28822271

Quality Earnings: 67N0 is currently unprofitable.

Growing Profit Margin: 67N0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 67N0 is unprofitable, but has reduced losses over the past 5 years at a rate of 26.7% per year.

Accelerating Growth: Unable to compare 67N0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 67N0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 67N0 has a negative Return on Equity (-49.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:24
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genor Biopharma Holdings Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
Yue-Kwong LuiJefferies LLC
Ling WangJ.P. Morgan